title: Is target oriented surgery sufficient with borderline ovarian tumors? - Role of accompanying pathologies.
abstract: BACKGROUND
  There are limited data in the literature related to concomitant genital or extra-genital organ pathologies in patients with borderline ovarian tumors (BOTs). The aim of this study was to evaluate our experience with 183 patients to draw attention to the accompanying organ pathologies with BOTs.
  
  
  METHODS
  One hundred eighty-three patients with BOTs, diagnosed and/or treated in our center between January of 2000 and March of 2013 were evaluated retrospectively. Data related to age, tumor histology, lesion side, disease stage, accompanying incidental ipsilateral and/or contralateral ovarian pathologies, treatment approaches, and follow-up periods were investigated. Incidental gynecologic and non-gynecologic concomitant organ pathologies were also recorded.
  
  
  RESULTS
  The mean age at diagnosis was 40.6 years (range: 17-78). Ninety- five patients (51%) were ≤40 years. A hundred and forty-seven patients (80%) were at stage IA of the disease. The most common type of BOT was serous in histology. Non-invasive tumor implants were diagnosed in 4% and uterine involvement was found 2% among patients who underwent hysterectomies. There were 12 patients with positive peritoneal washings. Only 17 and 84 patients respectively had concomitant ipsilateral and concomitant contralateral incidental ovarian pathologies. The most common type of uterine, appendicular and omental pathologies were chronic cervicitis, lymphoid hyperplasia and chronic inflammatory reaction.
  
  
  CONCLUSIONS
  According to our findings most of accompanying pathologies for BOT are benign in nature. Nevertheless, there were additional malignant diseases necessitating further therapy. We emphasize the importance of the evaluation of all abdominal organs during surgery.
authors.affiliation: Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey E-mail : cetinkayanilufer@gmail.com.
authors.forename: Tayfun
authors.initials: T
authors.lastname: Gungor
authors.forename: Nilufer
authors.initials: N
authors.lastname: Cetinkaya
authors.forename: Hakan
authors.initials: H
authors.lastname: Yalcin
authors.forename: Bulent
authors.initials: B
authors.lastname: Ozdal
authors.forename: Emre
authors.initials: E
authors.lastname: Ozgu
authors.forename: Eralp
authors.initials: E
authors.lastname: Baser
authors.forename: Nafiye
authors.initials: N
authors.lastname: Yilmaz
authors.forename: Mete
authors.initials: M
authors.lastname: Caglar
authors.forename: Sema
authors.initials: S
authors.lastname: Zergeroglu
authors.forename: Salim
authors.initials: S
authors.lastname: Erkaya
mesh_terms: D000232:Adenofibroma / Q000150:complications; D000293:Adolescent; D000328:Adult; D000368:Aged; D005871:Castleman Disease / Q000150:complications; D018291:Cystadenoma, Mucinous / Q000150:complications; D018293:Cystadenoma, Serous / Q000150:complications; D004715:Endometriosis / Q000150:complications; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000601:surgery; D010053:Ovary / Q000166:cytology / Q000473:pathology*; D012189:Retrospective Studies; D002575:Uterine Cervicitis / Q000150:complications; D055815:Young Adult